BioLineRx Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLRX research report →
About the company
BioLineRx Ltd. , an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer.
- CEO
- Philip A. Serlin
- IPO
- 2011
- Employees
- 28
- HQ
- Hevel Modi'in, IL
Price Chart
- Market Cap
- $14.29M
- P/E
- -1.39
- P/S
- 9.29
- P/B
- 0.80
- EV/EBITDA
- -1.74
- Div Yield
- 0.00%
- Gross Margin
- 74.67%
- Op Margin
- -780.21%
- Net Margin
- -633.83%
- ROE
- -47.86%
- ROIC
- -36.68%
- Revenue
- $1.19M · -95.89%
- Net Income
- $-1,184,321 · 87.16%
- EPS
- $-0.29 · -150.65%
- Op Income
- $-10,368,606
- FCF YoY
- 81.42%
- 52W High
- $5.06
- 52W Low
- $2.15
- 50D MA
- $3.08
- 200D MA
- $3.10
- Beta
- 0.62
- Avg Volume
- 49.92K
Get TickerSpark's AI analysis on BLRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Yan Shaoyu | other | 0 |
| Oct 5, 16 | PANEM SANDRA | other | 49,800 |
| Oct 5, 17 | PANEM SANDRA | other | 19,800 |
| Oct 5, 18 | PANEM SANDRA | other | 19,800 |
| Oct 2, 19 | PANEM SANDRA | other | 199,800 |
| Oct 2, 20 | PANEM SANDRA | other | 79,800 |
| Oct 2, 21 | PANEM SANDRA | other | 79,800 |
| Oct 3, 24 | PANEM SANDRA | other | 360,000 |
| Oct 3, 23 | PANEM SANDRA | other | 360,000 |
| Jan 1, 25 | PANEM SANDRA | other | 2,055,000 |
Our BLRX coverage
Recent articles, reports, and earnings notes.
No research on BLRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BLRX report →Similar companies
Peers in the same neighborhood.